Percentage of L monocytogenes- and Y enterocolitica-infected 3d-, 5d-, and 7d-HSCs treated with different infection media
| . | No additive . | + 10% fetal calf serum . | + 10% human serum . | + 10% human serum + mannan (5 mg/mL) . |
|---|---|---|---|---|
| L monocytogenes | ||||
| 3d-HSCs | 7.3%* (SD 1.2) | 8.4% (SD 0.6) | 12.0% (SD 1.0) | 12.7% (SD 2.3) |
| 5d-HSCs | 8.3%† (SD 0.6) | 13.7%† (SD 0.6) | 22.0% (SD 1.0) | 20.0% (SD 1.7) |
| 7d-HSCs | 1.6%† (SD 1.1) | 4.0%† (SD 2.5) | 26.0% (SD 2.6) | 27.0% (SD 2.0) |
| Y enterocolitica | ||||
| 3d-HSCs | 12.3% (SD 2.1) | 10.7% (SD 2.5) | 13.7% (SD 1.5) | 9.4%* (SD 2.1) |
| 5d-HSCs | 15.0%* (SD 1.0) | 15.7%* (SD 3.2) | 22.4% (SD 2.1) | 15.3%* (SD 0.6) |
| 7d-HSCs | 10.4%† (SD 1.5) | 14.3%† (SD 4.0) | 36.0% (SD 2.1) | 22.0%† (SD 2.9) |
| . | No additive . | + 10% fetal calf serum . | + 10% human serum . | + 10% human serum + mannan (5 mg/mL) . |
|---|---|---|---|---|
| L monocytogenes | ||||
| 3d-HSCs | 7.3%* (SD 1.2) | 8.4% (SD 0.6) | 12.0% (SD 1.0) | 12.7% (SD 2.3) |
| 5d-HSCs | 8.3%† (SD 0.6) | 13.7%† (SD 0.6) | 22.0% (SD 1.0) | 20.0% (SD 1.7) |
| 7d-HSCs | 1.6%† (SD 1.1) | 4.0%† (SD 2.5) | 26.0% (SD 2.6) | 27.0% (SD 2.0) |
| Y enterocolitica | ||||
| 3d-HSCs | 12.3% (SD 2.1) | 10.7% (SD 2.5) | 13.7% (SD 1.5) | 9.4%* (SD 2.1) |
| 5d-HSCs | 15.0%* (SD 1.0) | 15.7%* (SD 3.2) | 22.4% (SD 2.1) | 15.3%* (SD 0.6) |
| 7d-HSCs | 10.4%† (SD 1.5) | 14.3%† (SD 4.0) | 36.0% (SD 2.1) | 22.0%† (SD 2.9) |
The results from a representative experiment are presented as mean values and SDs of triplicate determination.
P < .05 and †P < .001 byt test.